18F-FDG PET/CT: Normal Variants, Artifacts, and Pitfalls in Lung Cancer
- 775 Downloads
18F-2-Fluoro-2-deoxyglucose (FDG) is the workhorse of oncological PET/CT departments. Its role in staging, restaging, and response assessment of various cancers is already established. But FDG is a marker of glycolysis and, thus, is neither specific for malignancy nor for a particular tumor. Its accumulation can be seen in benign process which may be difficult to differentiate from a neoplastic etiology. It is imperative that nuclear physicians and radiologists know about these FDG-avid benign pathologies and few FDG-negative malignant etiologies, which may confound correct interpretation in PET/CT reporting.
- 20.Kamel EM, Goerres GW, Burger C, et al. Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET/CT image fusion—report of six cases. Radiology. 2002;224:153–6.Google Scholar
- 23.Lee SK, Rho BH, Won KS. Parotid incidentaloma identified by combined 18F-fluorodeoxyglucose whole-body positron emission tomography and computed tomography: findings at gray-scale and power Doppler ultrasonography and ultrasound-guided fine-needle aspiration biopsy or core biopsy. Eur Radiol. 2009;19:2268–74.CrossRefPubMedGoogle Scholar